Scarica l'app Stockscreener
1.02
4.08%
0.04
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
Clearmind Medicine files patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - TradingView
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times
Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World
Clearmind Medicine Inc (CMND) requires closer examination - uspostnews.com
Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - TradingView
Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - The Manila Times
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading - Bluefield Daily Telegraph
Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior - marketscreener.com
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior - TradingView
Clearmind Medicine Launches First U.S. Clinical Site For FDA-Approved Alcohol Use Disorder Trial - Nasdaq
Clearmind Medicine begins phase I/IIa trial for AUD treatment - Investing.com
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder at Johns Hopkins University - Nasdaq
Clearmind Medicine Launches First U.S. Clinical Site For Its FDA-Approved Clinical Trial To Combat Alcoholism - MarketScreener
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial - Yahoo Finance
Clearmind Medicine (CMND) Launches U.S. Clinical Trial for Alcoh - GuruFocus
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder - The Manila Times
Clearmind Medicine files patent for new psychedelic compounds - Investing.com
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - The Manila Times
Clearmind Medicine stock hits 52-week low at $0.95 By Investing.com - Investing.com South Africa
Clearmind Medicine stock hits 52-week low at $0.95 - Investing.com Australia
Clearmind launches data system for alcohol addiction trial - Investing.com
Clearmind Implements EDC System To Streamline Phase I/II Trial For Alcohol Use Disorder Drug - Nasdaq
Clearmind Medicine launches EDC system to support Phase I/II trial - TipRanks
Clearmind launches data system for alcohol addiction trial By Investing.com - Investing.com Australia
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment - The Manila Times
Psychedelic Revolution: Inside Clearmind Medicine's Breakthrough - AInvest
Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Yahoo Finance
Clearmind’s AUD drug candidate arrives in the U.S. for trials By Investing.com - Investing.com South Africa
Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US - MarketScreener
Clearmind’s AUD drug candidate arrives in the U.S. for trials - Investing.com
Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - The Manila Times
Clearmind Medicine Inc. Announces Arrival of CMND-100 in the U.S. Ahead of Phase I/IIa Trial for Alcohol Use Disorder - Nasdaq
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - TradingView
Clearmind and Polyrizon partner on nasal drug delivery By Investing.com - Investing.com South Africa
Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon - Nasdaq
Clearmind and Polyrizon partner on nasal drug delivery - Investing.com
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination - The Manila Times
Clearmind begins phase I/IIa trial for AUD treatment - Investing.com Australia
Clearmind Medicine Advances CMND-100 To Clinical Trials For Alcohol Use Disorder - Nasdaq
Clearmind Medicine Initiates First Clinical Trial Of CMND-100 For Alcohol Use Disorder Treatment - Nasdaq
Clearmind begins phase I/IIa trial for AUD treatment By Investing.com - Investing.com South Africa
Clearmind Begins Human Trials for Potential Psychedelic Treatment for Alcohol Abuse Patients - Marketscreener.com
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder Patients - Nasdaq
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in ... - The Bakersfield Californian
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):